Exchange: NASDAQ·Updated 05:12 AM EDT
ALT logo

ALTAltimmune Inc

$2.95
$0.03
(1.01%)
Pre-Market
Prev Close $2.98

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
Loading...

Fundamentals

Mkt Cap
$567.86M
52W High
$6.44
52W Low
$2.56
PE Ratio
-3.18
Avg. Volume
4.36M
EPS (Annual)
-$0.9999
Rev/Employee
$719.30
Earnings
Aug 11

Advertisement|Remove ads.

Advertisement|Remove ads.